In white mild to moderate hypertensive patients. Nifedipine Versus Captopril in the Management of Moderate Hypertension in Black ratients
|
|
- Gavin Perkins
- 5 years ago
- Views:
Transcription
1 A]H 1994; 7:440^47 Nifedipine Versus Captopril in the Management of Moderate Hypertension in Black ratients John Skoularigis, Leslie Eitzman, Jean Davis, Victor Strugo, and Pinhas Sareli The efficacy of nifedipine (20 to 40 mg twice daily) and Captopril (25 to 50 mg twice daily) was assessed during a 12-week single-blind randomized trial in 41 moderately hypertensive black patients (mean 24-h diastolic blood pressure [BP] > 90 mm Hg and < 115 mm Hg). Nifedipine and Captopril were administered as monotherapy in increasing dosage while a diuretic was added after 8 weeks in patients who failed to reach the target BP (24-h mean diastolic BP < 90 mm Hg) on monotherapy. After 8 weeks of monotherapy, the mean 24-h ambulatory BP was reduced from 156 ± 12/101 ± 5 to 128 ± 11/84 ± 7 mm Hg (P <.0001) in the nifedipine group while it remained essentially unchanged (156 ± 15/101 ± 7 to 158 ± 17/102 ± 9) in the Captopril group. Left ventricular (LV) mass index was also reduced significantly (P <.05) in the nifedipine group, while cardiac index and fractional shortening changed marginally. The addition of diuretic in the Captopril group (16/21 patients) resulted in a significant fall in BP to 123 ± 11/81 ± 7. Only 2/20 patients in the nifedipine group required the addition of diuretic. The overall incidence of side effects was similar with both treatments but the addition of diuretic in the Captopril group was followed by adverse changes in serum sodium (P <.01), urea (P <.05), and creatinine (P <.01) levels. It is concluded that nifedipine monotherapy offers an effective, safe firstline antihypertensive treatment in black patients with moderate hypertension while Captopril alone failed to control the BP. The combination of Captopril and diuretic, although more effective in controlling BP compared with Captopril alone, was associated with significant adverse metabolic effects. Am J Hypertens 1994;7: KEY WORDS: 24-h ambulatory blood pressure, nifedipine, Captopril, moderate hypertension, black patients. In white mild to moderate hypertensive patients calcium antagonists and angiotensin converting enzyme (ACE) inhibitors, commonly referred to as first-line antihypertensive agents, have approximately equal efficacy and favorable side-effect profiles. 12 Previous studies have shown that an optimal response to ACE inhibitors, especially in black patients, fairly frequently requires the addition of a Received August 16, Accepted December 20, From the Division of Cardiology, Baragwanath Hospital, Johannesburg, South Africa. Address correspondence and reprint requests to Dr. John Skoularigis, Division of Cardiology, Baragwanath Hospital, PO Bertsham 2013, Johannesburg, South Africa. diuretic. 3-6 However, most of our knowledge of the antihypertensive action of these drugs has been derived from conventional blood pressure (BP) measurements. Recently, ambulatory BP monitoring (ABPM) has become increasingly useful in the evaluation of drug efficacy because of its potential to overcome the well-known limitations inherent in conventional BP measurement. 7,8 Furthermore, the degree of BP "control" should be evaluated against the 24-h ABPM profiles of a matched control group rather than relying on an arbitrary diastolic BP value of 90 mm Hg as a measure of control. Thus, in the present study we (a) compared the BP lowering effects of tablet formulation of nifedipine 1994 by the American Journal of Hypertension, Ltd /94/$7.00
2 Α]Η-MAY 1994-VOL. 7, NO. 5 NIFEDIPINE ν CAPTOPRIL IN BLACK HYPERTENSIVES 441 (Adalat Retard, Bayer-Miles) and Captopril (Capoten, Bristol-Myers Squibb) by using 24-h ABPM, (b) compared them to an age-matched control group, (c) investigated whether combination with a diuretic could improve their antihypertensive effect, and (d) assessed their effect on left ventricular (LV) mass and systolic function, and metabolic parameters, in 41 consecutive black patients with moderate hypertension. METHODS Patient Population Subjects were 45 consecutive black patients between 21 and 65 years of age meeting two BP criteria: (1) an average sitting diastolic BP > 95 mm Hg and < 115 mm Hg, as a mean of 10 automated readings over a 30-min screening period using the Dinamap (Critikon 1846 SX Vital Signs Monitor), and (2) a 24-h mean diastolic ABPM > 90 mm Hg and < 115 mm Hg. The BP measurements were therefore free of observer bias. Patients were excluded from the study if they had secondary hypertension, hypertensive emergency, systolic BP > 215 mm Hg, congestive heart failure, history of recent (< 3 months) myocardial infarction or stroke, previous intolerance to dihydropyridines or Captopril, or hepatic or renal disorders. Additional screening procedures for entry included a comprehensive history and physical examination, full blood count, routine blood chemistry, urinalysis, chest roentgenogram, 12-lead electrocardiogram, 24-h ABPM and echo-doppler. The 24-h BP profiles and the echocardiographic parameters before and after therapy were compared with a matched control group of 40 normotensive subjects. The 24-h ABPM profiles and echo-doppler parameters were derived for the controls at a single visit using the same equipment as used for the hypertensives. All patients gave informed consent. Ethics Committee Approval This was obtained from both the Baragwanath Hospital Prescription and Therapeutics Committee and the Ethics Committee of the University of the Witwatersrand. Study Design The study comprised two phases: (1) a 3-week placebo-controlled baseline, and (2) a 12- week prospective randomized single-blind titration period with two treatment arms (nifedipine or Captopril). At randomization an initial dose of either 20 mg nifedipine twice daily or 25 mg Captopril twice daily was given for 6 weeks, the therapeutic goal being the reduction of sitting diastolic BP to < 90 mm Hg as measured by a 30-min Dinamap. If target diastolic BP was reached, patients continued at the same dose until the 12-week visit. The patients whose 30-min mean diastolic BP remained > 90 mm Hg after 6 weeks of active medication were titrated up to 40 or 50 mg twice daily, respectively, for a further 2 weeks. A second drug was added at the end of 8 weeks if the mean diastolic BP measured by 24-h ABPM was > 90 mm Hg using the maximum dose of nifedipine or Captopril. The second drug was Moduretic (50 mg hydrochlorothiazide and 5 mg amiloride HCl, Logos Ltd., South Africa) in doses of a half tablet daily for 2 weeks, increasing to 1 tablet daily for another 2 weeks according to BP response. Follow-up during the 12- week treatment period was done on a 2-week basis. Patients who experienced significant adverse effects, or reached a mean diastolic BP > 115 mm Hg at any titration point, were withdrawn from the study and placed on alternative therapy. Echo-Doppler evaluation and 24-h ABPM were performed at the end of each phase. Blood Pressure Measurement: Dinamap Method It was hypothesized that the use of a Dinamap as a screening device, especially when an average of multiple BP measurements is taken, eliminates observer bias, terminal digit preference, and reduces "white coat" hypertension. In this study, by using the Critikon 1846 SX vital signs monitor, BP was measured by an oscillometric technique at 3-min intervals for a total of 30 min. 9 Machines were calibrated against a mercury sphygmomanometer before use in each patient with maximum acceptable difference of ± 5 mm Hg at 200 mm Hg. 10 ABPM Continuous BP was measured with (oscillometric) SpaceLabs and monitors. Machines were calibrated against a mercury sphygmomanometer before use in each patient with the monitor readings being within 3 mm Hg or 2% of the manometer readings, whichever was greater. 11 From 6 AM to midnight BP and heart rate readings were taken every 15 min, and from midnight to 6 AM every 20 min. Daytime was defined as 6 AM to 6 PM. A 24-h ABPM recording was repeated if, during the 24-h period, any single hour had less than two successful readings. Mean BP was calculated from diastolic BP + V3 (systolic BP minus diastolic BP). 12 Importantly, for comparative purposes, all recordings were done under similar conditions. Echocardiography and Doppler Analysis M-mode and two-dimensional echocardiograms were obtained with the Hewlett Packard Sonos 500 or 1000 system using a 2.5-MHz transducer. Each patient was examined in the left lateral recumbent position. With the transducer in the left parasternal position, twodimensional guided M-mode echocardiography of the LV was performed immediately below the mitral valve leaflets at the chordal level in the short-axis view. 13 In the LV outflow tract, M-mode tracings were obtained at the aortic annulus directly proximal to the insertion of the aortic leaflets. Measurement of
3 442 SKOULARIGIS ET AL AJH-MAY 1994-VOL. 7, NO. 5 the aortic annulus was made at the inner edge of the endocardial echoes. Using two-dimensionally guided pulsed Doppler echocardiography, cardiac output was calculated as the product of the Doppler timevelocity integral, cross-sectional area, and heart rate. 14 During echocardiographic evaluation, simultaneous three-lead electrocardiogram and BP monitoring using a Dinamap were performed. Dinamap BP measurements were used in the calculation of the systemic vascular resistance. 15 M-mode variables were analyzed according to the American Society of Echocardiography convention 16 and included LV end-diastolic and end-systolic diameters and septal and posterior wall thickness. Fractional shortening was calculated as LV end-diastolic diameter minus LV end-systolic diameter divided by LV end-diastolic diameter. Doppler and M-mode recordings were videotaped and > 90% were made by the same experienced echocardiographer (JS), who was blinded to the BP and clinical data of the patient. The LV mass was derived according to an anatomically validated regression method which corrects LV mass estimates obtained from American Society of Echocardiography measurements. 17 Statistical Analysis Where the assumption of normality was not violated, the paired and Student's t tests were used for continuous data. When no proof of normality was available, nonparametric tests, ie, the U-test of Mann Whitney and Wilcoxon's signed ranked test for matched pairs, were used for between- and within-group comparisons, respectively. Adjustment of the Ρ value according to Bonferroni was used for pairwise comparisons. RESULTS Baseline demographics and 24-h ABPM profiles for the hypertensive and the control groups are shown in Table 1 and Figure 1, respectively. The difference in LV mass index between the nifedipine and Captopril groups can be explained by the higher percentage of male patients in the latter group. Safety Effects Forty-one of the 45 randomized patients completed the study (nifedipine, η = 20; Captopril, η = 21). One patient in each group was withdrawn because of adverse drug effects. The patient on nifedipine reported headache and peripheral edema, and the Captopril patient withdrew because of dizziness. One more patient in the nifedipine group was withdrawn due to social problems, while another captopril-treated patient died suddenly. The cause of death could not be ascertained as family refused postmortem examination. Previous to his death, BP appeared to respond to Captopril monotherapy and all laboratory tests were within normal limits. The analysis includes data for all 41 patients who completed the 12 weeks of treatment. Patient compliance, measured by tablet count throughout the study, was 98%. Drug Treatment At 12 weeks, nifedipine monotherapy controlled BP in 18 patients, at a dose of 20 mg twice daily in two and 40 mg twice daily in 16. In two further patients, although diuretic was added (both TABLE 1. BASELINE CLINICAL PARAMETERS OF THE HYPERTENSIVE AND NORMOTENSIVE SUBJECTS NIF (η = 20) CAP (n = 21) Controls (n = 40) Age (years) 47 ± ± 9 48 ± 10 Sex (males/females) 8/12 13/8 18/22 Body surface area (m 2 ) h ABP (mm Hg) Systolic 156 ± ± ± 8 Diastolic 101 ± ± 7 75 ± 6 Daytime ABP Systolic 162 ± ± ± 8 Diastolic 107 ± ± 7 81 ± 6 Nighttime ABP Systolic 150 ± ± ± 9 Diastolic 94 ± 7 94 ± 8 70 ± 7 Mean arterial pressure nocturnal decline (%) 10 ± 6 9 ± 6 11 ± 6 LV mass index (g/m 2 ) 108 ± 32* 130 ± 34* 61 ± 13 LV end-diastolic diameter (mm) 47 ± 4 48 ± 6 47 ± 4 LV end-systolic diameter (mm) 31 ± 5 32 ± 6 30 ± 4 Fractional shortening (%) 34 ± 6 32 ± 5 35 ± 4 Septum (mm) 10 ± 3* 11 ± 2* 7 ± 2 Posterior wall (mm) 9 ± 2 11 ± 2* 8 ± 2 *P <.05 NIF or CAP ν control. ABP, Ambulatory blood pressure; CAP, Captopril; LV, left ventricular; NIF, nifedipine.
4 AJH-MAY 1994-VOL. 7, NO. 5 NIFEDIPINE ν CAPTOPRIL IN BLACK HYPERTENSIVES 443 MEAN ARTERIAL PRESSURE τ Γ X ADALAT PRE HOURS CAPTOPRIL PRE )K ADALAT POST Φ CAPTOPRIL POST -["CONTROL FIGURE 1. Mean 24-h ambulatory mean arterial pressure profiles of the hypertensive subjects at baseline and after 8 weeks of treatment with nifedipine or Captopril ν normotensive controls. further 13 patients were controlled following the ad- dition of diuretic (seven on half a tablet daily and six on one tablet daily) while in three patients treatment failed to control the BP. on one tablet daily), BP control was not achieved. In the Captopril group, none of the patients was controlled on 25 mg twice daily, while five were controlled on monotherapy with 50 mg twice daily. A I I I I Γ TABLE 2. HEART RATE AND BLOOD PRESSURE DATA AT BASELINE AND AFTER 8 WEEKS OF TREATMENT WITH NIFEDIPINE OR CAPTOPRIL NIF (η = 20) CAP (η = 21) BLN 8 Weeks BLN 8 Weeks Dinamap BP Systolic 174 ± ± 18* 174 ± Diastolic 105 ± * 106 ± ± 6 24-h ABP Systolic 156 ± * 156 ± Diastolic ± ô 101 ± ±_ 9 Daytime ABP Systolic 162 ± ± 11* 162 ± Diastolic * 107 ± Nighttime ABP Systolic 150 ± ± 12* 150 ± Diastolic 94 ± * 94 ± 8 86 ± 3 24-h heart rate (beats/min) ± ± Mean arterial pressure nocturnal decline (%) 10 ± 6 12 ± 5 9 ± *P < weeks ν baseline. ABP, Ambulatory blood pressure (mm Hg), BLN, baseline.
5 444 SKOULARIGIS ET AL A]Η-MAY 1994-VOL. 7, NO. 5 TABLE 3. COMPARISON OF CAPTOPRIL ALONE WITH CAPTOPRIL AND DIURETIC CAP CAP + DRC (n = 16) (n 16) Dinamap BP Systolic 177 ± ± 19* Diastolic 110 ± * 24-h ABP Systolic 160 ± * Diastolic 106 ± 6 81 ± 7* Daytime ABP Systolic 164 ± ± 12* Diastolic 110 ±7 85 7* Nighttime ABP Systolic 156 ± ± 12* Diastolic 101 ± * 24-h heart rate (beats/min) 77 ± ± 13 *P <.0001 CAP + DRS ν CAP. ABP, Ambulatory blood pressure; CAP, Captopril, DRC, diuretic. 140 MEAN ARTERIAL PRESSURE Antihypertensive Effect Nifedipine monotherapy significantly reduced both the systolic and diastolic BP at 8 weeks compared with baseline, whether pressure was measured by Dinamap (15% and 9%, respectively) or by 24-h ABPM (18% and 17%, respectively) (Table 2 and Figure 1). The reduction observed was sustained for 24 h (Figure 1) and maintained up to 12 weeks. In contrast, in the Captopril group, a significant reduction in both systolic and diastolic BP was only shown at 12 weeks and this was after the addition of diuretic (Table 3 and Figure 2). As shown in Table 4, the relative changes in BP during monotherapy were significantly greater with nifedipine compared with Captopril (Ρ <.0001), suggestive of a greater hypotensive effect of nifedipine in these middle-aged black patients with moderate hypertension. Echocardiographic Data At 8 weeks, there was a significant decline in LV mass index when compared to baseline (16%, Ρ <.05) for the nifedipine group only, and this was due to a reduction in diastolic myocardial wall thickness (Table 5). With Captopril monotherapy, although there was a 10% reduction in baseline LV mass index, this failed to become significant. Neither the reduction in LV mass nor the use of nifedipine or Captopril was associated with a deterioration in cardiac function, since cardiac index, fractional shortening, and 24-h heart rate remained similar throughout the study. HOURS CONTROL Φ Captopril alone )K Captopril +Moduretic FIGURE 2. Mean 24-h ambulatory mean arterial pressure profiles of the 15 patients who required the addition of diuretic at baseline and after 12 weeks of treatment ν normotensive controls.
6 AJH-MAY 1994-VOL. 7, NO. 5 NIFEDIPINE ν CAPTOPRIL IN BLACK HYPERTENSIVES 445 TABLE 4. MEAN CHANGES FOR PATIENTS ON NIFEDIPINE ν CAPTOPRIL AT 8 WEEKS NIF CAP (n = 20) (n = 21) Dinamap BP Systolic * Diastolic 10 ± 7-3 ± 8* 24-h ABP Systolic 28 ± 13-1 ± 11* Diastolic 17 ± 8-1 ± 8* LV mass index (g/m 2 ) 16 ± ± 36 LV end-diastolic diameter (mm) -0.1 ± ± 5 LV end-systolic diameter (mm) 1.1 ± ± 7 Fractional shortening (%) -1.6 ± Septum (mm) o-.i ± 0.3 Posterior wall (mm) 0.1 ± ± 0.3 Cardiac index (L/min/m 2 ) -0.3 ± ± 0.5 Minus sign indicates that the baseline was smaller in value. *P <.0001 CAP ν MF. ABP, Ambulatory blood pressure; CAP, Captopril; LV, left ventricular; NIF, nifedipine. Side Effects The well-documented side-effects of headache (20% for nifedipine, 10% for Captopril), dizziness (5% for both), and pedal edema (15% and 0%, respectively) were noted at the end of the study. Only one patient in each group was withdrawn as a result of side effects. Neither treatment induced metabolic changes, although the addition of diuretic in the Captopril group was followed by adverse changes in serum sodium (P <.01), urea (P <.05), and creatinine (P <.01) levels (Table 6). No changes in serum potassium levels were observed following the combination of Captopril and a potassium-sparing diuretic (Table 6). No significant changes in physical findings or body weight were noted in either treatment group. DISCUSSION The major findings of this study were: (1) nifedipine, but not Captopril, significantly reduced both systolic and diastolic BP in middle-aged black patients with moderate hypertension as measured by 24-h ABPM; (2) the marked anithypertensive effect of nifedipine was accompanied by a reduction in LV mass on the order of 16% with no adverse effect on LV systolic performance; (3) the addition of Moduretic to Captopril produced a pronounced fall in BP and this fall was related to the dose of diuretic; and (4) the combination of Captopril and Moduretic resulted in significant adverse metabolic effects. The need for an effective, safe first-line drug that can be administered without repeated laboratory tests during chronic management of hypertension in black patients led us to evaluate in this study the relative efficacy and side effects of a calcium antagonist compared with an ACE inhibitor. Thus, for the first time, using 24-h ABPM, a direct comparison of nifedipine with Captopril has been done in black patients with moderate hypertension. Previous studies comparing calcium antagonists with ACE inhibitors were mainly done in white hypertensive patients and yielded comparable results. 1 In the study by Saunders et al, 18 the calcium antagonist verapamil, when compared with atenolol and Captopril, appeared particularly effective as monotherapy in lowering both systolic and diastolic BP in black patients with mild to moderate hypertension. Compared with our study, there are major differences, as we included patients with more severe hypertension, evaluated BP control by using 24-h ABPM, and assessed LV mass and function by echocardiography. Furthermore, the BP reduction achieved with nifedipine monotherapy in our study was not only greater than the one observed previously, 18 but was also significantly more pronounced than with Captopril, and was sustained for 24 h and maintained for up to 12 weeks. This greater responsiveness of hypertensive black patients to nifedipine than to Captopril could be related to their TABLE 5. ECHO-DOPPLER PARAMETERS BEFORE AND AFTER 8 WEEKS OF NIFEDIPINE OR CAPTOPRIL THERAPY NIF (η = 17) CAP (η = 16) BLN 8 Weeks BLN 8 Weeks Septum (mm) 10 ± 3 Posterior wall (mm) 9 ± 2 LV end-diastolic diameter (mm) 47 4 LV end-systolic diameter (mm) 31 ± 5 LV mass index (g/m 2 ) 108 ± 32 Fractional shortening (%) 34 ± 6 Cardiac index (L/min/m 2 ) 2.5 ± 0.4 Systemic vascular resistance index 40 7 (dynes-sec-cm 5 x 10 2 ) 9 ± 2* 11 ± ± 2* ± 5 48 ± 6 48 ± 6 30 ± 3 32 ± ± 30* 130 ± ± 5 33 ± ± ± 7t 45 ± 9 38 ± 8+ *P <.05 and fp < weeks ν BLN. BLN, Baseline; CAP, Captopril; LV, left ventricular; NIF, nifedipine.
7 446 SKOULARIGIS ET AL AJH-MAY 1994-VOL. 7, NO. 5 TABLE 6. LABORATORY DATA BEFORE AND AFTER 12 WEEKS OF NIFEDIPINE OR CAPTOPRIL THERAPY NIF (η = 20) CAP (η = 21) Baseline 12 Weeks Baseline 12 Weeks Sodium (mmol/l) 140 ± ± ± ± 5t Potassium (mmol/l) 4.0 ± ± ± ± 0.7 Urea (mmol/l) 4.6 ± ± ± ± 2.6* Creatinine (μιηοι/l) 78 ± ± ± ± 31+ Glucose (mmol/l) 4.8 ± ± ± ± 0.9 Uric acid (mmol/l) 0.4 ± ± ± ± 0.1 Cholesterol (mmol/l) 5.1 ± ± ± ± 1.2 *P <.05 and fp < weeh ν baseline. CAP, Captopril; NIF, nifedipine. average low plasma renin activity. However, it is not easy to predict whether or not ACE inhibitor monotherapy would be effective in a given patient because of the multifactorial causation of hypertension and the multimechanism mode of action of ACE inhibitors. In addition, there have been studies showing that ACE inhibitor therapy becomes more effective in the presence of concurrent diuretic therapy.^ These findings were further confirmed by our study, as the combination of Captopril with Moduretic produced a significant fall in BP which was related to the dose of diuretic, as there was a further fall in BP in the six patients whose dose was increased to one tablet daily. The antihypertensive effect of nifedipine was due to a marked reduction (20%) in systemic vascular resistance (Table 5). However, although Captopril caused a significant reduction (15%) in systemic vascular resistance, it also increased the cardiac output and therefore the BP remained essentially unchanged. In the treatment of hypertension, regression of an elevated LV mass is desirable. 19 As in our previous study, 20 a reduction in diastolic myocardial wall thickness following control of BP with nifedipine resulted in a significant decrease (16%) in LV mass index (Table 5), while LV internal dimensions and systolic function were unaltered. With Captopril monotherapy, despite the failure of BP control, there was a nonsignificant reduction (10%) in LV mass index. However, this is beyond the 5.2% variation in echocardiographic measurements at our laboratory and may be attributed to a direct myocardial tissue effect. Although nifedipine or Captopril monotherapy did not affect the biochemical and hematologic variables tested, the addition of diuretic in the Captopril group was associated with significant adverse metabolic effects compared with the metabolic profile of nifedipine, raising doubts as to its use when laboratory monitoring is not readily available. These findings have practical significance in the choice of a suitable antihypertensive regimen in individual patients. A dose of 20 to 40 mg nifedipine twice daily will reduce BP steadily and without precipitous drop in most black patients with moderate essential hypertension. REFERENCES 1. Opie LH: ACE-inhibitors for hypertension, in Opie LH (ed): Angiotensin Converting Enzyme Inhibitors. New York, Authors' Publishing House, 1992, pp Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993;153: Bauer JH, Jones LB: Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension. Am J Kidney Dis 1984;4: Kayanakis JG, Baulac L: The comparative study of once-daily administration of Captopril 50 mg, hydrochlorothiazide 25 mg and their combination in mild to moderate hypertension. Br J Clin Pharmacol 1987;27: 289S-296S. 5. MacGregor G A, Markandu ND, Banks RA, et al: Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propanolol. Br Med J 1982;284: Brown CL, Backhouse CI, Grippβt JC, et al: The effect of Perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the reninangiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990;39: Mancia G, Omboni S, Parati G, et al: Ambulatory blood pressure monitoring in the design of studies on antihypertensive drug efficacy. Am J Hypertens 1993; 6:233S-235S. 8. White WB, Grinn JM, McCabe EJ: Clinical usefulness of ambulatory blood pressure monitoring. Am J Hypertens 1993;6:225S-228S. 9. Borow KM, Newburger JW: Noninvasive estimation of central aortic pressure using the oscillometric method for analysing systemic artery pulsatile blood flow: comparative study of indirect systolic, diastolic, and mean brachial artery pressure with simultaneous
8 AJH-MAY 1994-VOL 7, NO. 5 NIFEDIPINE ν CAPTOPRIL IN BLACK HYPERTENSIVES 447 direct ascending aortic pressure measurements. Am Heart J 1982;103: Dinamap 1846 SX: Adult/pediatric and neonatal vital signs monitor. Operation manual. Tampa, Florida, Critikon, Inc., 1986, pp Ambulatory Blood Pressure Monitor: Operations/ technical manual. Redmond, Washington, SpaceLabs, Inc., 1988, pp Berk JL, Sampliner JE: Handbook of Critical Care, Ed. 2. Boston, Little, Brown and Company, Devereux RB, Liebson PR, Horan MJ: Recommendations concerning use of echocardiography in hypertension and general population research. Hypertension 1987;9(suppl II):II-97-II Dittman H, Voelfer W, Karsch K, et al: Influence of sampling site and flow area on cardiac output measurements by Doppler echocardiography. J Am Coll Cardiol 1987;10: Grossman W: Clinical measurement of vascular resistance and assessment of vasodilator drugs, in Grossman W (ed): Cardiac Catheterization and Angiography, Ed. 3. Philadelphia, Lea & Febiger, 1986, pp Sahn DJ, DeMaria A, Kisslo J, et al: The Committee on Standardization of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58: Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: Saunders E, Weir MR, Kong W, et al: A comparison of the efficacy and safety of a ί-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150: Levy D, Garrison RJ, Savage DD, et al: Prognostic significance of echocardiographically determined left ventricular mass in the Framingham Heart Study. Ν Engl J Med 1990;322: Middlemost SJ, Sack M, Davis J, et al: Effects of longacting nifedipine on casual office blood pressure measurements, 24-hour ambulatory blood pressure profiles, exercise parameters and left ventricular mass and function in black patients with mild to moderate systemic hypertension. Am J Cardiol 1992;70:
PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING M-MODE ECHOCARDIOGRAPHY
Malaysian Journal of Medical Sciences, Vol. 9, No. 1, January 22 (28-33) ORIGINAL ARTICLE PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING
More informationPrevalence of left ventricular hypertrophy in a hypertensive population
European Heart Journal (1996) 17, 143-149 Prevalence of left ventricular hypertrophy in a hypertensive population J. Tingleff, M. Munch, T. J. Jakobsen, C. Torp-Pedersen, M. E. Olsen, K. H. Jensen, T.
More informationEchocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?
Journal of Human Hypertension (1999) 13, 505 509 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Echocardiographic definition of left ventricular
More informationDIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI.
DIFFERENTE RELAZIONE TRA VALORI PRESSORI E MASSA VENTRICOLARE SX NEI DUE SESSI IN PAZIENTI IPERTESI. Franco Cipollini, Carlo Porta, Enrica Arcangeli, Carla Breschi, & Giuseppe Seghieri Azienda USL 3, Ambulatorio
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationBRIEF COMMUNICATIONS. KEY WORDS: Ambulatory blood pressure monitoring, placebo effect, antihypertensive drug trials.
AJH 1995; 8:311-315 BRIEF COMMUNICATIONS Lack of Placebo Effect on Ambulatory Blood Pressure Giuseppe Mancia, Stefano Omboni, Gianfranco Parati, Antonella Ravogli, Alessandra Villani, and Alberto Zanchetti
More informationDoes the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy?
(24) 18, S23 S28 & 24 Nature Publishing Group All rights reserved 95-92/4 $3. www.nature.com/jhh ORIGINAL ARTICLE Does the reduction in systolic blood pressure alone explain the regression of left ventricular
More informationAortic stenosis (AS) is common with the aging population.
New Insights Into the Progression of Aortic Stenosis Implications for Secondary Prevention Sanjeev Palta, MD; Anita M. Pai, MD; Kanwaljit S. Gill, MD; Ramdas G. Pai, MD Background The risk factors affecting
More informationAngiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with Arterial Hypertension*
The Journal of International Medical Research 2005; 33 (Suppl 1): 21A 29A Angiotensin II Receptor Blocker Telmisartan: Effect on Blood Pressure Profile and Left Ventricular Hypertrophy in Patients with
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHigh-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension
(2005) 19, 491 496 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE High-dose monotherapy vs low-dose combination therapy of calcium channel blockers
More informationHow well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study
(2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationIntroduction. In Jeong Cho, MD, Wook Bum Pyun, MD and Gil Ja Shin, MD ABSTRACT
ORIGINAL ARTICLE DOI 10.4070 / kcj.2009.39.4.145 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright c 2009 The Korean Society of Cardiology The Influence of the Left Ventricular Geometry on the Left
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationONLINE DATA SUPPLEMENT. Impact of Obstructive Sleep Apnea on Left Ventricular Mass and. Diastolic Function
ONLINE DATA SUPPLEMENT Impact of Obstructive Sleep Apnea on Left Ventricular Mass and Diastolic Function Mitra Niroumand Raffael Kuperstein Zion Sasson Patrick J. Hanly St. Michael s Hospital University
More informationLeft Ventricular Systolic and Diastolic Function and Mass before and after Antihypertensive Treatment in Patients with Essential Hypertension
23 Left Ventricular Systolic and Diastolic Function and Mass before and after Antihypertensive Treatment in Patients with Essential Hypertension Yuji Yoshitomi, Toshio Nishikimi, Hitoshi Abe, Seiki Nagata,
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationVerapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design
Br J Clin Pharmacol 1998; 45: 491 495 Verapamil SR and trandolapril combination therapy in hypertension a clinical trial of factorial design Juergen Scholze, 1 Peter Zilles 2 & Daniele Compagnone 2 on
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationHemodynamic Assessment. Assessment of Systolic Function Doppler Hemodynamics
Hemodynamic Assessment Matt M. Umland, RDCS, FASE Aurora Medical Group Milwaukee, WI Assessment of Systolic Function Doppler Hemodynamics Stroke Volume Cardiac Output Cardiac Index Tei Index/Index of myocardial
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationHypertension is a common disease in our
AJH 2000;13:1161 1167 Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on or Trefor O. Morgan, Adrianne Anderson, and Denise Bertram Arthritis and
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationChanges in Left Atrial Size in Patients with Lone Atrial Fibrillation
Clin. Cardiol. 14,652-656 (1991) Changes in Left Atrial Size in Patients with Lone Atrial Fibrillation GUILLERMO SOSA SUAREZ, M.D., SIEVEN LAMPERT, M.D., F.A.C.C., SHMUEL RAVID, M.D., BERNARD LOWN, M.D.,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationThe Evolution To Treatment Of Hypertension With Advanced Formulation
The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High
More informationBaroreflex sensitivity and the blood pressure response to -blockade
Journal of Human Hypertension (1999) 13, 185 190 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Baroreflex sensitivity and the blood pressure
More informationhydrochlorothiazide in the treatment of moderate arterial
Br. J. clin. Pharmac. (1987), 23, 65S-69S Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension D. STERU1, M. CHILDS', S. LANCRENON',
More informationThe management of hypertension has become
AJH 1997;10:743 749 Additive Effects of Diltiazem and Lisinopril in the Treatment of Elderly Patients With Mild-to-Moderate Hypertension Paul Chan, Chun-Nan Lin, Brian Tomlinson, Tz-Hsin Lin, and Ying-Shiung
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationOverview of the outcome trials in older patients with isolated systolic hypertension
Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated
More informationMyocardial performance index, Tissue Doppler echocardiography
Value of Measuring Myocardial Performance Index by Tissue Doppler Echocardiography in Normal and Diseased Heart Tarkan TEKTEN, 1 MD, Alper O. ONBASILI, 1 MD, Ceyhun CEYHAN, 1 MD, Selim ÜNAL, 1 MD, and
More informationComparison of arbitrary definitions of circadian time periods with those determined by wrist actigraphy in analysis of ABPM data
Journal of Human Hypertension (1999) 13, 449 453 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 http://www.stockton-press.co.uk/jhh ORIGINAL ARTICLE Comparison of arbitrary definitions of
More informationThe hypertensive effects of the renin-angiotensin
Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring George Bakris, MD A prospective, randomized, open-label, blinded end-point
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationAssessing Blood Pressure for Clinical Research: Pearls & Pitfalls
Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls Anthony J. Viera, MD, MPH, FAHA Department of Family Medicine Hypertension Research Program UNC School of Medicine Objectives Review limitations
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationMANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM
MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM Are Particular Anti-hypertensives More Effective or Harmful Than Others in Hypertension in Pregnancy? Existing data is inadequate Methyldopa and
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationRegression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study Peter M. Okin, MD; Richard B. Devereux,
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationAbody of evidence demonstrates that alcohol
BRIEF COMMUNICATIONS AJH 1998;11:230 234 The Effects of Alcohol Consumption on Ambulatory Blood Pressure and Target Organs in Subjects With Borderline to Mild Hypertension Olga Vriz, Diana Piccolo, Enrico
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationMareomi Hamada, Go Hiasa, Osamu Sasaki, Tomoaki Ohtsuka, Hidetoshi Shuntaro Ikeda, Makoto Suzuki, Yuji Hara, and Kunio Hiwada
297 Original Article Serum Creatinine Level Renal Involvement Essential Underestimates Hypertensive in Elderly Patients with Hypertension Yuji Shigematsu, Mareomi Hamada, Go Hiasa, Osamu Sasaki, Tomoaki
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY. Introduction. Patients and Methods
Vol. 2, Issue 1, pages 31-36 ORIGINAL ARTICLE AMBULATORY BLOOD PRESSURE IN OBESITY By Alejandro de la Sierra, MD Luis M. Ruilope, MD Hypertension Units, Hospital Clinico, Barcelona & Hospital 12 de Octubre,
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationORIGINAL ARTICLE. LEFT VENTRICULAR MASS INDEX: A PREDICTOR OF MORBIDITY AND MORTALITY IN ESSENTIAL HYPERTENSION Pooja Shashidharan 1
LEFT VENTRICULAR MASS INDEX: A PREDICTOR OF MORBIDITY AND MORTALITY IN ESSENTIAL HYPERTENSION Pooja Shashidharan 1 HOW TO CITE THIS ARTICLE: Pooja Shashidharan. Left ventricular mass index: a predictor
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationNight time blood pressure and cardiovascular structure in a middle-aged general population in northern Italy: the Vobarno Study
(2001) 15, 879 885 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Night time blood pressure and cardiovascular structure in a middle-aged general
More informationIndirect ambulatory blood pressure monitoring devices
AJH 1992;5:880-886 Comparison of Ambulatory and Clinic Blood Pressure and Heart Rate in Older Persons With Isolated Systolic Hypertension Gale H. Rutan, Robert H. McDonald, and Lewis H. Kuller We compared
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationEchocardiographic and Doppler Assessment of Cardiac Functions in Patients of Non-Insulin Dependent Diabetes Mellitus
ORIGINAL ARTICLE JIACM 2002; 3(2): 164-8 Echocardiographic and Doppler Assessment of Cardiac Functions in Patients of Non-Insulin Dependent Diabetes Mellitus Rajesh Rajput*, Jagdish**, SB Siwach***, A
More informationInternet Journal of Medical Update, Vol. 3, No. 2, Jul-Dec 2008
Evaluation of left ventricular structures in normotensive and hypertensive subjects by two-dimensional echocardiography: Anthropometric correlates in hypertension Mr. Ugwu Anthony Chukwuka * MSc, Mr. Okwor
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationInterventricular Septum Thickness Predicts Future Systolic Hypertension in Young Healthy Pilots
15 Original Article Hypertens Res Vol.31 (2008) No.1 p.15-20 Interventricular Septum Thickness Predicts Future Systolic Hypertension in Young Healthy Pilots Chagai GROSSMAN 1), Alon GROSSMAN 2), Nira KOREN-MORAG
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationLeft Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient
Left Ventricular Diastolic Dysfunction in South Indian Essential Hypertensive Patient Dr. Peersab.M. Pinjar 1, Dr Praveenkumar Devarbahvi 1 and Dr Vasudeva Murthy.C.R 2, Dr.S.S.Bhat 1, Dr.Jayaraj S G 1
More informationLarge therapeutic studies in elderly patients with hypertension
(2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional
More information& Wilkins. a Division of Cardiology, Schulich Heart Centre, b Institute for Clinical and
Original article 333 Optimum frequency of office blood pressure measurement using an automated sphygmomanometer Martin G. Myers a, Miguel Valdivieso a and Alexander Kiss b,c Objective To determine the
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationANTI- HYPERTENSIVE AGENTS
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
More informationESSENTIAL HYPERTENSION
E S S E N T I A L H Y P E R T E N S I O N Elevated blood pressure is one of the most important causes of cardiovascular disease. J A Ker MB ChB, MMed, MD Professor and Deputy Dean Faculty of Health Sciences
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationAppendix II: ECHOCARDIOGRAPHY ANALYSIS
Appendix II: ECHOCARDIOGRAPHY ANALYSIS Two-Dimensional (2D) imaging was performed using the Vivid 7 Advantage cardiovascular ultrasound system (GE Medical Systems, Milwaukee) with a frame rate of 400 frames
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationDIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING
DIURNAL VARIATIONS IN BLOOD PRESSURE AND THEIR RELATION WITH CAROTID ARTERY INTIMA-MEDIA THICKENING Sh Narooei (1), B Soroor (2), F Zaker (3) Abstract INTRODUCTION: Hypertension is a very common cardiovascular
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationThe incidence of transient myocardial ischemia,
AJH 1999;12:50S 55S Heart Rate and the Rate-Pressure Product as Determinants of Cardiovascular Risk in Patients With Hypertension William B. White Inability to supply oxygen to the myocardium when demand
More informationdoi: /01.CIR
Effect of Single-Drug Therapy on Reduction of Left Atrial Size in Mild to Moderate Hypertension: Comparison of Six Antihypertensive Agents John S. Gottdiener, Domenic J. Reda, David W. Williams, Barry
More informationClinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127
Hypertension in adults: diagnosis and management Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationClinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDr. A. Manjula, No. 7, Doctors Quarters, JLB Road, Next to Shree Guru Residency, Mysore, Karnataka, INDIA.
Original Article In hypertensive patients measurement of left ventricular mass index by echocardiography and its correlation with current electrocardiographic criteria for the diagnosis of left ventricular
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More information